St. Louis Financial Planners Asset Management increased its holdings in Johnson & Johnson by 35.3% in Q4, now owning 22,422 shares worth $4.64 million, making it their 8th largest position. The company recently received FDA approval for Icotyde, an oral IL-23 receptor antagonist, boosting its immunology portfolio with significant revenue potential. Analysts from HSBC and Morgan Stanley raised price targets, signaling confidence in J&J's growth prospects. Despite insider stock sales and some cautious ratings, Johnson & Johnson maintains strong fundamentals with a recent quarterly dividend and positive earnings results, supporting a moderate buy consensus among analysts.
Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of ...
Johnson & Johnson reported solid Q2 2026 results, achieving 6.6% annual revenue growth driven by strong Pharma and MedTech divisions. The company maintains a portfolio of over 15 blockbuster drugs and a promising pipeline, supporting its status as a ...
Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable...
The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
